OXiGENE Inc. (OXGN) announced after the close Thursday that the European Medicines Agency has granted orphan drug designation for ZYBRESTAT for the treatment of ovarian cancer.
OXiGENE gapped open sharply higher Friday and is now up 0.99 at $3.49 on above average volume. The stock has risen to over a 1-month high and has re-crossed its 50-day moving average.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org